 Shares of Aldeyra Therapeutics Inc NASDAQ: ALDX, a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi initiated coverage of Aldeyra shares with a Buy rating and 24 price target. 